Syros Pharmaceuticals (NASDAQ:SYRS - Get Free Report) was upgraded by investment analysts at StockNews.com from a "sell" rating to a "hold" rating in a research note issued on Thursday.
Syros Pharmaceuticals Trading Down 8.4 %
Shares of NASDAQ:SYRS traded down $0.49 during mid-day trading on Thursday, reaching $5.35. 318,061 shares of the company's stock were exchanged, compared to its average volume of 198,902. The firm has a market capitalization of $112.72 million, a price-to-earnings ratio of -1.43 and a beta of 1.79. The business's fifty day moving average price is $6.86 and its 200-day moving average price is $5.06. The company has a debt-to-equity ratio of 1.09, a quick ratio of 4.31 and a current ratio of 4.31. Syros Pharmaceuticals has a twelve month low of $2.09 and a twelve month high of $8.17.
Hedge Funds Weigh In On Syros Pharmaceuticals
A number of hedge funds have recently bought and sold shares of the company. Two Sigma Investments LP raised its stake in Syros Pharmaceuticals by 30.0% during the first quarter. Two Sigma Investments LP now owns 13,600 shares of the company's stock worth $36,000 after buying an additional 3,139 shares during the last quarter. Renaissance Technologies LLC increased its stake in Syros Pharmaceuticals by 8.0% in the fourth quarter. Renaissance Technologies LLC now owns 47,235 shares of the company's stock valued at $170,000 after purchasing an additional 3,500 shares in the last quarter. Price T Rowe Associates Inc. MD increased its stake in Syros Pharmaceuticals by 85.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 22,550 shares of the company's stock valued at $61,000 after purchasing an additional 10,400 shares in the last quarter. LPL Financial LLC increased its stake in Syros Pharmaceuticals by 13.1% in the second quarter. LPL Financial LLC now owns 94,075 shares of the company's stock valued at $296,000 after purchasing an additional 10,886 shares in the last quarter. Finally, Shay Capital LLC increased its stake in Syros Pharmaceuticals by 87.3% in the second quarter. Shay Capital LLC now owns 26,426 shares of the company's stock valued at $83,000 after purchasing an additional 12,317 shares in the last quarter. Institutional investors own 91.47% of the company's stock.
Syros Pharmaceuticals Company Profile
(
Get Free Report)
Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Syros Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Syros Pharmaceuticals wasn't on the list.
While Syros Pharmaceuticals currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
